Edition:
United States

Herbalife Ltd (HLF.N)

HLF.N on New York Stock Exchange

63.26USD
28 Apr 2017
Change (% chg)

$0.32 (+0.51%)
Prev Close
$62.94
Open
$62.95
Day's High
$63.28
Day's Low
$62.72
Volume
104,858
Avg. Vol
200,493
52-wk High
$72.20
52-wk Low
$47.62

HLF.N

Chart for HLF.N

About

Herbalife Ltd. is a global nutrition company. The Company develops and sells weight management, healthy meals and snacks, sports and fitness, energy and targeted nutritional products, as well as personal care products. Its operating segments are based on geographical operations in six regions: North America; Mexico; South and... (more)

Overall

Beta: 1.64
Market Cap(Mil.): $5,888.58
Shares Outstanding(Mil.): 93.09
Dividend: --
Yield (%): --

Financials

  HLF.N Industry Sector
P/E (TTM): 21.00 66.45 40.43
EPS (TTM): 3.01 -- --
ROI: 16.11 6.40 61.89
ROE: 364.15 9.82 73.26

Senators press Icahn on White House influence, business conflicts

WASHINGTON Several Democratic senators pressed billionaire investor Carl Icahn on Monday to clarify his role as an adviser to President Donald Trump, saying his position in the administration raised "alarming" questions about potential conflicts of interest with his stakes in the biofuels and pharmaceutical industries.

Mar 27 2017

Senators press Icahn on White House influence, business conflicts

WASHINGTON Several Democratic senators pressed billionaire investor Carl Icahn on Monday to clarify his role as an adviser to President Donald Trump, saying his position in the administration raised "alarming" questions about potential conflicts of interest with his stakes in the biofuels and pharmaceutical industries.

Mar 27 2017

Senators press Icahn on White House influence, business conflicts

WASHINGTON, March 27 Several Democratic senators pressed billionaire investor Carl Icahn on Monday to clarify his role as an adviser to President Donald Trump, saying his position in the administration raised "alarming" questions about potential conflicts of interest with his stakes in the biofuels and pharmaceutical industries.

Mar 27 2017

Senate panel presses SEC nominee Clayton on conflicts

WASHINGTON Jay Clayton, the Wall Street attorney tapped by President Donald Trump to lead the U.S. Securities and Exchange Commission, on Thursday defended himself against Democrats' charges that multiple conflicts of interest would force him to miss too many SEC votes.

Mar 23 2017

UPDATE 4-U.S. Senate panel presses SEC nominee Clayton on conflicts

WASHINGTON, March 23 Jay Clayton, the Wall Street attorney tapped by President Donald Trump to lead the U.S. Securities and Exchange Commission, on Thursday defended himself against Democrats' charges that multiple conflicts of interest would force him to miss too many SEC votes.

Mar 23 2017

U.S. Senate panel presses SEC nominee Clayton on conflicts

WASHINGTON Jay Clayton, the Wall Street attorney tapped by President Donald Trump to lead the U.S. Securities and Exchange Commission, on Thursday defended himself against Democrats' charges that multiple conflicts of interest would force him to miss too many SEC votes.

Mar 23 2017

BRIEF-Herbalife CEO fy 2016 total compensation $10.9 mln - sec filing

* CEO Michael Johnson's fy 2016 total compensation $10.9 million versus $9.9 million in fy 2015 - SEC filing Source text for Eikon: Further company coverage:

Mar 13 2017

BRIEF-Carl Icahn reports purchase of 372,324 shares of Herbalife on Mar. 10 2017

* Carl Icahn reports purchase of 372,324 shares of Herbalife's common stock on March 10, 2017 at $51.35 per share - SEC filing Source text: (http://bit.ly/2n0phgW) Further company coverage:

Mar 13 2017

BRIEF-Carl Icahn reports 24.57 pct stake in Herbalife Ltd as of March 10

* Carl Icahn reports 24.57 percent stake in Herbalife Ltd as on March 10, 2017 - SEC filing

Mar 13 2017

BRIEF-Syngene International & Herbalife partner to establish nutrition R&D lab in India

* Says Herbalife nutrition partners with Syngene to establish nutrition research and development lab in India

Mar 02 2017

More From Around the Web

Earnings vs. Estimates